Juliette Thariat, Antoine Moya Plana, Benjamin Vérillaud, Sébastien Vergez, François Régis-Ferrand, Laurence Digue, Caroline Even, Valérie Costes, Bertrand Baujat, Ludovic de Gabory, Anne-Catherine Baglin, François Janot
Sinonasal carcinomas account for 3% of ENT cancers. They are subdivided into squamous cell carcinomas (50%), adenocarcinomas [20%, mostly of intestinal type (ITAC)], and more rarely, adenoid cystic carcinomas, olfactory neuroblastomas (=esthesioneuroblastomas), neuroendocrine carcinomas or undifferentiated sinonasal carcinomas (SNUC). The 5-year survival rates are, in descending order, 72% for neuroblastomas, 63% for adenocarcinomas, 50-60% for large-cell neuroendocrine carcinomas, 53% for squamous cell carcinomas, 25-50% for adenoid cystic, 35% for small-cell neuroendocrine carcinomas and 35% for SNUC and newly discovered histologies...
May 2020: Bulletin du Cancer